Bush Jason R, Alfa Michelle J
MSP Starch Products Inc., Carberry, MB, Canada.
Department of Biology, Brandon University, Brandon, MB, Canada.
BMC Nutr. 2020 Dec 11;6(1):72. doi: 10.1186/s40795-020-00398-9.
Prebiotics, defined as a substrate that is selectively utilized by host microorganisms conferring a health benefit, present a potential option to optimize gut microbiome health. Elucidating the relationship between specific intestinal bacteria, prebiotic intake, and the health of the host remains a primary microbiome research goal.
To assess the correlations between gut microbiota, serum health parameters, and prebiotic consumption in healthy adults.
We performed ad hoc exploratory analysis of changes in abundance of genera in the gut microbiome of 75 participants from a randomized, placebo-controlled clinical trial that evaluated the effects of resistant potato starch (RPS; MSPrebiotic®, N = 38) intervention versus a fully digestible placebo (N = 37) for which primary and secondary outcomes have previously been published. Pearson correlation analysis was used to identify relationships between health parameters (ie. blood glucose and lipids) and populations of gut bacteria.
Abundance of Parasutterella (phylum Proteobacteria) tended to increase in the gut microbiome of individuals consuming RPS and those increases in Parasutterella were correlated with reductions in low-density lipoprotein (LDL) levels in participants consuming RPS but not placebo. Segregating RPS-consuming individuals whose LDL levels decreased (ie "Responders") from those who did not (ie. "Non-Responders") revealed that LDL Responders had significantly higher levels of Parasutterella both at baseline and after 12 weeks of consuming RPS.
Our analyses suggest that RPS may help improve LDL levels depending upon the levels of Parasutterella in an individual's gut microbiome.
This study protocol was reviewed and approved by Health Canada (Submission #188517; "Notice of Authorization" dated 06/05/13) and registered as NCT01977183 (10/11/13) listed on NIH website: ClinicalTrials.gov. Data generated in this study have been submitted to NCBI ( http://www.ncbi.nlm.nih.gov/bioproject/381931 ).
MSP Starch Products Inc.
益生元被定义为一种能被宿主微生物选择性利用并带来健康益处的底物，是优化肠道微生物群健康的一个潜在选择。阐明特定肠道细菌、益生元摄入与宿主健康之间的关系仍然是微生物群研究的主要目标。
评估健康成年人肠道微生物群、血清健康参数和益生元消费之间的相关性。
我们对一项随机、安慰剂对照临床试验的75名参与者的肠道微生物群中属的丰度变化进行了专项探索性分析，该试验评估了抗性马铃薯淀粉（RPS；MSPrebiotic®，N = 38）干预与完全可消化安慰剂（N = 37）的效果，此前已发表了主要和次要结果。使用Pearson相关分析来确定健康参数（即血糖和血脂）与肠道细菌群体之间的关系。
在食用RPS的个体的肠道微生物群中，副萨特氏菌属（变形菌门）的丰度往往会增加，食用RPS的参与者中副萨特氏菌属的增加与低密度脂蛋白（LDL）水平的降低相关，但食用安慰剂的参与者则不然。将食用RPS后LDL水平降低的个体（即“反应者”）与未降低的个体（即“无反应者”）分开显示，LDL反应者在基线时和食用RPS 12周后副萨特氏菌属的水平显著更高。
我们的分析表明，RPS可能有助于改善LDL水平，这取决于个体肠道微生物群中副萨特氏菌属的水平。
本研究方案已由加拿大卫生部审查并批准（提交编号188517；2013年5月6日的“授权通知”），并在NIH网站ClinicalTrials.gov上注册为NCT01977183（2013年11月10日）。本研究产生的数据已提交给NCBI（http://www.ncbi.nlm.nih.gov/bioproject/381931）。
MSP淀粉产品公司
